DK1017413T3 - Flydende formulering af interferon-beta - Google Patents

Flydende formulering af interferon-beta

Info

Publication number
DK1017413T3
DK1017413T3 DK98950074T DK98950074T DK1017413T3 DK 1017413 T3 DK1017413 T3 DK 1017413T3 DK 98950074 T DK98950074 T DK 98950074T DK 98950074 T DK98950074 T DK 98950074T DK 1017413 T3 DK1017413 T3 DK 1017413T3
Authority
DK
Denmark
Prior art keywords
beta
buffered
interferon
liquid formulation
hsa
Prior art date
Application number
DK98950074T
Other languages
English (en)
Other versions
DK1017413T4 (da
Inventor
Michael Tschoepe
Thomas Siklosi
Peter Schroeder
Hans Hofer
Original Assignee
Rentschler Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1017413(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rentschler Biotech Gmbh filed Critical Rentschler Biotech Gmbh
Publication of DK1017413T3 publication Critical patent/DK1017413T3/da
Application granted granted Critical
Publication of DK1017413T4 publication Critical patent/DK1017413T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Gyroscopes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK98950074T 1997-09-23 1998-09-23 Flydende formulering af interferon-beta DK1017413T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116562 1997-09-23
PCT/EP1998/006065 WO1999015193A1 (de) 1997-09-23 1998-09-23 FLÜSSIGE INTERFERON-β-FORMULIERUNGEN

Publications (2)

Publication Number Publication Date
DK1017413T3 true DK1017413T3 (da) 2003-02-03
DK1017413T4 DK1017413T4 (da) 2008-03-25

Family

ID=8227392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98950074T DK1017413T4 (da) 1997-09-23 1998-09-23 Flydende formulering af interferon-beta

Country Status (13)

Country Link
US (2) US6923956B1 (da)
EP (3) EP1017413B2 (da)
JP (1) JP4293497B2 (da)
KR (2) KR100711990B1 (da)
AT (2) ATE224726T1 (da)
AU (1) AU741300B2 (da)
CA (1) CA2304808C (da)
DE (2) DE59811910D1 (da)
DK (1) DK1017413T4 (da)
ES (2) ES2223017T5 (da)
IL (3) IL135186A0 (da)
PT (2) PT1224940E (da)
WO (1) WO1999015193A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DK1017413T4 (da) † 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US8338374B2 (en) 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
UA88300C2 (ru) * 2004-05-17 2009-10-12 Эйрес Трейдинг С.А. Гидрогелевые композиции, которые содержат интерферон
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
MXPA06014079A (es) * 2004-06-01 2007-02-15 Ares Trading Sa Metodo para estabilizar proteinas.
KR101191536B1 (ko) * 2004-06-01 2012-10-15 아레스 트레이딩 에스.에이. 안정화된 인터페론 액상 제제
ES2318575T3 (es) * 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
DK1917276T3 (da) * 2005-08-26 2018-05-07 Ares Trading Sa Fremgangsmåde til fremstilling af glycosyleret Interferon Beta
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
DE102008060960A1 (de) * 2008-12-06 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Optische Füllstandsmessung
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP2919801B1 (en) * 2012-10-26 2020-04-29 Lupin Atlantis Holdings, SA Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept
US9649383B2 (en) * 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
DE3177213D1 (de) 1980-04-03 1990-10-18 Biogen Inc Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
DE3262575D1 (en) † 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59181224A (ja) † 1983-03-29 1984-10-15 Sumitomo Chem Co Ltd 安定なインタ−フエロン製剤の製法
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
EP0284249A1 (en) † 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
US4895716A (en) † 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
EP0374257B1 (en) * 1988-05-06 1994-08-31 Toray Industries, Inc. STABLE INTERFERON $g(b) COMPOSITION
US5272135A (en) † 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
JPH06247870A (ja) 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
SI0948358T2 (sl) 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
DK1017413T4 (da) † 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta

Also Published As

Publication number Publication date
ES2223017T5 (es) 2010-10-15
EP1426058A3 (de) 2004-07-28
ES2181281T5 (es) 2008-04-16
ATE274917T1 (de) 2004-09-15
CA2304808A1 (en) 1999-04-01
EP1017413A1 (de) 2000-07-12
AU741300B2 (en) 2001-11-29
EP1224940A1 (de) 2002-07-24
KR20010015599A (ko) 2001-02-26
DE59805732D1 (de) 2002-10-31
EP1224940B1 (de) 2004-09-01
JP4293497B2 (ja) 2009-07-08
EP1017413B1 (de) 2002-09-25
KR100826621B1 (ko) 2008-05-02
US20050186177A1 (en) 2005-08-25
EP1426058A2 (de) 2004-06-09
KR20060088910A (ko) 2006-08-07
CA2304808C (en) 2011-03-22
EP1017413B2 (de) 2007-11-07
DK1017413T4 (da) 2008-03-25
IL211048A (en) 2012-12-31
KR100711990B1 (ko) 2007-05-02
PT1224940E (pt) 2005-01-31
IL135186A0 (en) 2001-05-20
ES2223017T3 (es) 2005-02-16
IL135186A (en) 2012-12-31
ES2181281T3 (es) 2003-02-16
PT1017413E (pt) 2003-02-28
ATE224726T1 (de) 2002-10-15
US6923956B1 (en) 2005-08-02
AU9627698A (en) 1999-04-12
US8337826B2 (en) 2012-12-25
EP1224940A8 (de) 2002-11-20
WO1999015193A1 (de) 1999-04-01
EP1224940B2 (de) 2010-08-11
JP2001517635A (ja) 2001-10-09
DE59811910D1 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
DK1017413T4 (da) Flydende formulering af interferon-beta
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
DE69428040D1 (de) Orale darreichungsform
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
DE502004012418D1 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
TW427905B (en) Aqueous pharmaceutical composition of nerve growth factor
ATE255450T1 (de) Matrix für iontophorese
ES2167939T3 (es) Nuevas poliaminas, su preparacion y usos.
WO1996005286A3 (en) Cell death accelerator and cell death inhibitor
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
马贵斌 et al. Studies on the Interaction of Multimolecular Systems by Fluorescent Probe of Terbium Ion
IT8820978A0 (it) Composizione erbicida conselettivita' aumentata e processo per la preparazione di entrambi i componenti ingredienti attivi in un solo stadio.
NZ509773A (en) Casein formulations for the delivery of bioactive constituents
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle